Last reviewed · How we verify
MMRV (AMP) — Competitive Intelligence Brief
phase 3
Live attenuated combination vaccine
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
MMRV (AMP) (MMRV (AMP)) — Merck Sharp & Dohme LLC. MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating adaptive immune responses to all four viruses.
Comparator set (3 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MMRV (AMP) TARGET | MMRV (AMP) | Merck Sharp & Dohme LLC | phase 3 | Live attenuated combination vaccine | ||
| ProQuad® | ProQuad® | Merck Sharp & Dohme LLC | marketed | Live attenuated combination vaccine | ||
| Comparator: ProQuad™ (V221) | Comparator: ProQuad™ (V221) | Merck Sharp & Dohme LLC | phase 3 | Live attenuated combination vaccine | ||
| MMRV (2006 process) | MMRV (2006 process) | Merck Sharp & Dohme LLC | phase 3 | Live attenuated combination vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Live attenuated combination vaccine class)
- Merck Sharp & Dohme LLC · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MMRV (AMP) CI watch — RSS
- MMRV (AMP) CI watch — Atom
- MMRV (AMP) CI watch — JSON
- MMRV (AMP) alone — RSS
- Whole Live attenuated combination vaccine class — RSS
Cite this brief
Drug Landscape (2026). MMRV (AMP) — Competitive Intelligence Brief. https://druglandscape.com/ci/mmrv-amp. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab